Since thrombospondin-1 stimulates cell migration and may potentially contribute to the spread of cancer, blocking TSP1–CD47 interaction may be another novel therapeutic approach in CTCL. Here, THBS1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.